Practical management of everolimus-related toxicities in patients with advanced solid tumors

Onkologie(Czech Republic)

Volumn 36, Issue 5, 2013, Pages 295-302

  Grünwald, Viktor ^a   Weikert, Steffen ^b   Pavel, Marianne E ^b   Hörsch, Dieter ^c   Lüftner, Diana ^b   Janni, Wolfgang ^d   Geberth, Matthias ^e   Weber, Matthias M ^f  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c ZENTRALKLINIK BAD BERKA   (Germany)

^d UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^e Institut für Gynäkologische Onkologie   (Germany)

^f UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

Adverse event; Everolimus; Management; mTOR; Safety; Toxicity

Indexed keywords

ACICLOVIR; ANTIHISTAMINIC AGENT; CETYLPYRIDINIUM SALT; CORTICOSTEROID; ENTECAVIR; EVEROLIMUS; FLUCONAZOLE; METHYLPREDNISOLONE; MOUTHWASH; ORAL ANTIDIABETIC AGENT; PHOSPHATE; PREDNISOLONE; SORAFENIB; STREPSILS; TENOFOVIR; UNCLASSIFIED DRUG;

ADVANCED CANCER; ARTICLE; ASPERGILLOSIS; BACTERIAL INFECTION; CANCER CHEMOTHERAPY; CANDIDIASIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMPUTER ASSISTED TOMOGRAPHY; CORTICOSTEROID THERAPY; COUGHING; CREATININE BLOOD LEVEL; DISEASE SEVERITY; DYSPNEA; EARLY INTERVENTION; GRANULOMATOUS INFLAMMATION; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPOPHOSPHATEMIA; HYPOXIA; INFECTION RISK; LIVER FAILURE; LUNG FIBROSIS; LYMPHOCYTIC INFILTRATION; MACULOPAPULAR RASH; OPPORTUNISTIC INFECTION; ORGANIZING PNEUMONIA; PATIENT EDUCATION; PHASE 3 CLINICAL TRIAL (TOPIC); PLEURA EFFUSION; PNEUMONIA; PRURITUS; QUALITY OF LIFE; RASH; RESPIRATORY FAILURE; RHINOPHARYNGITIS; SEPSIS; SIDE EFFECT; SOLID TUMOR; STOMATITIS; TREATMENT OUTCOME; URINARY TRACT INFECTION; VASCULITIS; VIRUS INFECTION; X RAY;

ANTINEOPLASTIC AGENTS; HUMANS; INFECTION; INFECTION CONTROL; INFLAMMATION; NEOPLASMS; SIROLIMUS;

EID: 84878217451     PISSN: 0378584X     EISSN: 14230240     Source Type: Journal    
DOI: 10.1159/000350625     Document Type: Article

References (46)

1. Edinger AL, Thompson CB: Akt maintains cell size and survival by increasing mTOR-dependent nutrient uptake. Mol Biol Cell 2002;13: 2276-2288.
2. Humar R, Kiefer FN, Berns H, Resink TJ, Battegay EJ: Hypoxia enhances vascular cell proliferation and angiogenesis in vitro via rapamycin (mTOR)-dependent signaling. FASEB J 2002;16: 771-780.
3. Laplante M, Sabatini DM: mTOR signaling in growth control and disease. Cell 2012;149: 274-293.
4. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, Wykoff CC, Pugh CW, Maher ER, Ratcliffe PJ: The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999;399: 271-275.
5. Lane HA, Breuleux M: Optimal targeting of the mTORC1 kinase in human cancer. Curr Opin Cell Biol 2009;21: 219-229.
6. Zoncu R, Efeyan A, Sabatini DM: mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 2011;12: 21-35.
7. Afinitor® (everolimus) tablets (package insert). East Hanover, NJ, Novartis, 2012. www.accessdata.fda.gov/drugsatfda-docs/label/2012/022334s018lbl. pdf (accessed February 26, 2013).
8. Afinitor® (everolimus) tablets (summary of product characteristics). Horsham, UK, Novartis Europharm Limited, 2012. www.ema.europa.eu/docs/en-GB/ document-library/EPAR-Product-Information/human/001038/WC500022814.pdf (accessed February 26, 2013).
9. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grunwald V, Thompson JA, Figlin RA, Hollaender N, Kay A, Ravaud A: Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors. Cancer 2010;116: 4256-4265.
10. Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EG, Tomassetti P, Pavel ME, Hoosen S, Haas T, Lincy J, Lebwohl D, Oberg K: Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011;364: 514-523.
11. Baselga J, Campone M, Piccart M, Burris HA, 3rd, Rugo HS, Sahmoud T, Noguchi S, Gnant M, Pritchard KI, Lebrun F, Beck JT, Ito Y, Yardley D, Deleu I, Perez A, Bachelot T, Vittori L, Xu Z, Mukhopadhyay P, Lebwohl D, Hortobagyi GN: Everolimus in postmenopausal hormone-receptorpositive advanced breast cancer. N Engl J Med 2012;366: 520-529.
12. Piccart M, Baselga J, Noguchi S, Burris H, Gnant M, Hortobagyi G, Mukhopadhyay P, Taran T, Sahmoud T, Rugo H: Final progressionfree survival analysis of BOLERO-2: a phase III trial of everolimus for postmenopausal women with advanced breast cancer. Presentation at the CTRC-AACR San Antonio Breast Cancer Symposium, 4-8 December 2012, San Antonio, TX, USA; abstr P6-04-02.
13. Votubia® (everolimus) tablets (summary of product characteristics). Horsham, UK, Novartis Europharm Limited, 2012. www.ema.europa.eu/docs/en-GB/ document-library/EPAR-Product-Information/human/002311/WC500112238.pdf (accessed February 26, 2013).
14. Pavel ME, Hainsworth JD, Baudin E, Peeters M, Horsch D, Winkler RE, Klimovsky J, Lebwohl D, Jehl V, Wolin EM, Oberg K, Van Cutsem E, Yao JC: Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet 2011;378: 2005-2012.
15. Kostler WJ, Hejna M, Wenzel C, Zielinski CC: Oral mucositis complicating chemotherapy and/or radiotherapy: options for prevention and treatment. CA Cancer J Clin 2001;51: 290-315.
16. Boers-Doets CB, Epstein JB, Raber-Durlacher JE, Ouwerkerk J, Logan RM, Brakenhoff JA, Lacouture ME, Gelderblom H: Oral adverse events associated with tyrosine kinase and mammalian target of rapamycin inhibitors in renal cell carcinoma: a structured literature review. Oncologist 2012;17: 135-144.
17. Sonis S, Treister N, Chawla S, Demetri G, Haluska F: Preliminary characterization of oral lesions associated with inhibitors of mammalian target of rapamycin in cancer patients. Cancer 2010;116: 210-215.
18. Porta C, Osanto S, Ravaud A, Climent MA, Vaishampayan U, White DA, Creel P, Dickow B, Fischer P, Gornell SS, Meloni F, Motzer RJ: Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma. Eur J Cancer 2011;47: 1287-1298.
19. De Oliveira MA, Martins EMF, Wang Q, Sonis S, Demetri G, George S, Butrynski J, Treister NS: Clinical presentation and management of mTOR inhibitor-associated stomatitis. Oral Oncol 2011;47: 998-1003.
20. Pilotte AP, Hohos MB, Polson KM, Huftalen TM, Treister N: Managing stomatitis in patients treated with Mammalian target of rapamycin inhibitors. Clin J Oncol Nurs 2011;15:E83-89.
21. Eisen T, Sternberg CN, Robert C, Mulders P, Pyle L, Zbinden S, Izzedine H, Escudier B: Targeted therapies for renal cell carcinoma: review of adverse event management strategies. J Natl Cancer Inst 2012;104: 93-113.
22. Campistol JM, de Fijter JW, Flechner SM, Langone A, Morelon E, Stockfleth E: mTOR inhibitor- associated dermatologic and mucosal problems. Clin Transplant 2010;24: 149-156.
23. Potting CM, Uitterhoeve R, Op Reimer WS, Van Achterberg T: The effectiveness of commonly used mouthwashes for the prevention of chemotherapy- induced oral mucositis: a systematic review. Eur J Cancer Care (Engl) 2006;15: 431-439.
24. Stokman MA, Spijkervet FK, Boezen HM, Schouten JP, Roodenburg JL, de Vries EG: Preventive intervention possibilities in radiotherapyand chemotherapy-induced oral mucositis: results of meta-analyses. J Dent Res 2006;85: 690-700.
25. Ryan AJ, Lin F, Atayee RS: Ketamine mouthwash for mucositis pain. J Palliat Med 2009;12: 989-991.
26. Dodd MJ, Dibble SL, Miaskowski C, MacPhail L, Greenspan D, Paul SM, Shiba G, Larson P: Randomized clinical trial of the effectiveness of 3 commonly used mouthwashes to treat chemotherapy- induced mucositis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2000;90: 39-47.
27. Chuang P, Langone AJ: Clobetasol ameliorates aphthous ulceration in renal transplant patients on sirolimus. Am J Transplant 2007;7: 714-717.
28. Cho D, Signoretti S, Regan M, Mier JW, Atkins MB: The role of mammalian target of rapamycin inhibitors in the treatment of advanced renal cancer. Clin Cancer Res 2007;13: 758s-763s.
29. Duran I, Siu LL, Oza AM, Chung TB, Sturgeon J, Townsley CA, Pond GR, Seymour L, Niroumand M: Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus. Eur J Cancer 2006;42: 1875-1880.
30. Albiges L, Chamming's F, Duclos B, Stern M, Motzer RJ, Ravaud A, Camus P: Incidence and management of mTOR inhibitor-associated pneumonitis in patients with metastatic renal cell carcinoma. Ann Oncol 2012;23: 1943-1953.
31. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grunwald V, Thompson JA, Figlin RA, Hollaender N, Urbanowitz G, Berg WJ, Kay A, Lebwohl D, Ravaud A: Efficacy of everolimus in advanced renal cell carcinoma: a doubleblind, randomised, placebo-controlled phase III trial. Lancet 2008;372: 449-456.
32. Anandappa G, Hollingdale A, Eisen T: Everolimus - a new approach in the treatment of renal cell carcinoma. Cancer Manag Res 2010;2: 61-70.
33. Creel P, Moldawer NP: Noninfectious pneumonitis in a patient with renal cell carcinoma treated with everolimus. Oncol Nurs Forum 2011;38: 125-128.
34. White DA, Camus P, Endo M, Escudier B, Calvo E, Akaza H, Uemura H, Kpamegan E, Kay A, Robson M, Ravaud A, Motzer RJ: Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma. Am J Respir Crit Care Med 2010;182: 396-403.
35. Moldawer NP, Wood LS: Management of key adverse events associated with everolimus therapy. Kidney Cancer J 2010;8: 51-59.
36. Di Lorenzo G, Porta C, Bellmunt J, Sternberg C, Kirkali Z, Staehler M, Joniau S, Montorsi F, Buonerba C: Toxicities of targeted therapy and their management in kidney cancer. Eur Urol 2011; 59: 526-540.
37. Rodriguez-Pascual J, Cheng E, Maroto P, Duran I: Emergent toxicities associated with the use of mTOR inhibitors in patients with advanced renal carcinoma. Anticancer Drugs 2010;21: 478-486.
38. Benjamin EM: Self-monitoring of blood glucose: the basics. Clinical Diabetes 2002;20: 45-47.
39. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B: Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009;32: 193-203.
40. Busaidy NL, Farooki A, Dowlati A, Perentesis JP, Dancey JE, Doyle LA, Brell JM, Siu LL: Management of metabolic effects associated with anticancer agents targeting the PI3K-Akt-mTOR pathway. J Clin Oncol 2012;30: 2919-2928.
41. Ewald N, Hardt PD, Kloer HU: Severe hypertriglyceridemia and pancreatitis: presentation and management. Curr Opin Lipidol 2009;20: 497-504.
42. National Institutes of Health. National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Final report. www.nhlbi.nih.gov/guidelines/cholesterol/atp3full.pdf.
43. International task force for prevention of coronary heart disease. Treatment guidelines for dyslipidemia. www.chd-taskforce.com/pdf/2004-06-09- zurich. pdf.
44. Genest J, Frohlich J, Fodor G, McPherson R: Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update. CMAJ 2003; 169: 921-924.
45. Guevremont C, Alasker A, Karakiewicz PI: Management of sorafenib, sunitinib, and temsirolimus toxicity in metastatic renal cell carcinoma. Curr Opin Support Palliat Care 2009;3: 170-179.
46. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009;50: 227-242.